Impact of Evolocumab in Cardiac Transplant Patients With CAV
Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
Coronary allograft vasculopathy (CAV) is diffusely accelerated atherosclerosis of a
transplanted heart. Evolocumab (repatha) is an FDA-approved drug for lowering LDL in patients
who have not received a heart transplant. This drug works as a PCSK9-inhibitor. The primary
objective of this study is to measure the impact of PCSK9-inhibitors on serum LDL in heart
transplant patients with CAV after 12 weeks compared to baseline.